Recent Updates
Recently added Catalysts

ARQ-154

Phase 2

Seborrheic Dermatitis | Small molecule | Dermatology |Arcutis Biotherapeutics, Inc.|Last Updated: Jun 11, 2024

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment408
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT04445987Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic DermatitisPHASE2 COMPLETED 408Jun 12, 2020Nov 19, 2022Jun 11, 202439 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Participants With ≥1 Adverse Event (AE)
Up to 52 weeks

The number of participants with treatment-emergent AEs is reported. An AE is any untoward or unfavorable medical occurrence in a human participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to participation in the research. Data are presented according to cohort group assigned as treatment were identical in this study regardless of the treatment received in the prior study.

Number of Participants With ≥1 Serious Adverse Event (SAE)
Up to 52 weeks

The number of participants with treatment-emergent SAEs is reported. An SAE is any AE that results in death, is life-threatening (places the subject at immediate risk of death from the event as it occurred), requires inpatient hospitalization or prolongation of existing hospitalization, results in a persistent or significant disability/incapacity, results in a congenital anomaly/birth defect, or is any other adverse event that, based upon appropriate medical judgment, may jeopardize the subject's health. Data are presented according to cohort group assigned as treatment were identical in this study regardless of the treatment received in the prior study.

Secondary Endpoints
Number of Participants With an Investigator Global Assessment (IGA) Score of Completely Clear or Almost Clear
Weeks 4, 12, 24, 36, and 52
Achievement of IGA Success
Weeks 4, 12, 24, 36, and 52
Duration of IGA Success
Weeks 4, 12, 24, 36, and 52
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Long-term safety of ARQ-154EXPERIMENTALOpen-label, Long-term Safety of ARQ-154
Interventions
NameTypeDescription
ARQ-154DRUGARQ-154 foam 0.3% applied once daily for 52 weeks
Unlock Study Design Details
Eligibility Criteria
Age Range9 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites39

Inclusion Criteria: 1. Participants legally competent to sign and give informed consent or (for adolescents) assent. 2. Males and females ages 9 years and older (inclusive) at the time of consent. 3. Females of childbearing potential (FOCBP) must have a negative serum pregnancy test at all study vi...

Countries:United States
Unlock Eligibility Criteria